Positive Clinical Data from Endologix Suprarenal Study to Be Introduced March 19 at SCVS Symposium
March 13 2009 - 4:00AM
Business Wire
Endologix, Inc. (NASDAQ: ELGX), the developer and manufacturer
of the Powerlink� System for the minimally invasive treatment of
abdominal aortic aneurysms (AAA), today announced that data from
its prospective, multicenter clinical trial of the Powerlink
Suprarenal Proximal Extension System will be presented for the
first time on March 19, 2009 at the Society for Clinical Vascular
Surgery�s (SCVS) 37th Annual Symposium being held in Ft.
Lauderdale, Fla. Endologix is currently marketing the Powerlink
Suprarenal Extensions following receipt of U.S. Food and Drug
Administration approval in October 2008.
Stuart A. Harlin, M.D., FACS, of Sacred Heart Medical Center in
Pensacola, Fla., who was a principal investigator in this trial,
will discuss the data and results in a presentation entitled, �EVAR
Using an Anatomical Fixation Technique and Concomitant Suprarenal
Orientation: Results of a Prospective, Multicenter Trial.�
Endologix plans to announce these clinical data in a press release
to be issued following the presentation.
The Powerlink Suprarenal Proximal Extension is designed with an
open cell stent extending above the graft material to allow the
physician to position the device at the proximal landing zone
without obstructing renal arteries. The device is available in
multiple diameters and lengths and can treat patients with aortic
necks up to 32 millimeters in diameter.
�We are pleased with the continued exceptional clinical results
from the Powerlink device and look forward to sharing this
information with the vascular community at the SCVS symposium,�
said John McDermott, Endologix President and CEO. �The Powerlink
System includes the only available unibody stent graft for the
treatment of AAA that facilitates anatomical fixation. The
availability of proximal extensions in suprarenal or infrarenal
configuration gives physicians a clinical choice for the treatment
of a wide range of patient anatomies, including large diameter
aortic necks.�
About Endologix
Endologix, Inc. develops and manufactures innovative therapies
for aortic disorders. The company�s IntuiTrak System is an
endovascular stent graft for treating abdominal aortic aneurysms
(AAA). AAA is a weakening of the wall of the aorta, the largest
artery in the body, resulting in a balloon-like enlargement. Once
AAA develops, it continues to enlarge and, if left untreated,
becomes increasingly susceptible to rupture. The overall patient
mortality rate for ruptured AAA is approximately 75%, making it a
leading cause of death in the U.S. Additional information can be
found on Endologix�s Web site at www.endologix.com.
Except for historical information
contained herein, this news release contains forward-looking
statements, the accuracy of which are necessarily subject to risks
and uncertainties, all of which are difficult or impossible to
predict accurately and many of which are beyond the control of
Endologix. The Company undertakes no obligation to update its
forward-looking statements. Please refer to the Company�s Annual
Report on Form 10-K for the year ended December 31, 2008, and the
Company�s other filings with the Securities and Exchange
Commission, for more detailed information regarding these risks and
other factors that may cause actual results to differ materially
from those expressed or implied.
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jul 2023 to Jul 2024